SAN FRANCISCO, July 30, 2019 /PRNewswire/ -- Audentes
Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic
medicines company focused on developing and commercializing
innovative products for serious rare neuromuscular diseases, will
host a conference call and webcast to report its second quarter
2019 financial results and provide a corporate update on
Tuesday, August 6, 2019.
The conference call will be held at 4:30
pm ET. To access a live webcast of the conference call,
please visit the Events & Presentations page within the
Investor + Media section of the Audentes website at
www.audentestx.com. Alternatively, please call (833) 659-8620
(U.S.) or (409) 767-9247 (international) and dial the conference
ID# 4244738 to access the call.
A replay of the live webcast will be available on the Audentes
website for approximately 30 days.
About Audentes Therapeutics, Inc.
Audentes
Therapeutics (Nasdaq: BOLD) is a leading AAV-based genetic
medicines company focused on developing and commercializing
innovative products for serious rare neuromuscular diseases.
We are leveraging our AAV gene therapy technology platform and
proprietary manufacturing expertise to develop programs across
three modalities: gene replacement, vectorized exon skipping, and
vectorized RNA knockdown. Our product candidates are showing
promising therapeutic profiles in clinical and preclinical studies
across a range of neuromuscular diseases. Audentes is a
focused, experienced and passionate team driven by the goal of
improving the lives of patients.
For more information regarding Audentes, please visit
www.audentestx.com.
Audentes Contacts:
Investor Contact:
Andrew Chang
415.818.1033
achang@audentestx.com
Media Contact:
Sarah Spencer
415.957.2020
sspencer@audentestx.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/audentes-therapeutics-to-release-second-quarter-2019-financial-results-and-provide-corporate-update-on-tuesday-august-6-2019-300892711.html
SOURCE Audentes Therapeutics, Inc.
